Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
5,800
Employees5,800
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
5,800
Employees5,800

MRNA Key Statistics

Market cap
17.70B
Market cap17.70B
Price-Earnings ratio
-5.62
Price-Earnings ratio-5.62
Dividend yield
Dividend yield
Average volume
16.82M
Average volume16.82M
High today
$45.69
High today$45.69
Low today
$45.32
Low today$45.32
Open price
$45.48
Open price$45.48
Volume
43.36K
Volume43.36K
52 Week high
$55.20
52 Week high$55.20
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

With a market cap of 17.7B, Moderna(MRNA) trades at $45.35. The stock has a price-to-earnings ratio of -5.62.

On 2026-01-29, Moderna(MRNA) stock traded between a low of $45.32 and a high of $45.69. Shares are currently priced at $45.35, which is +0.1% above the low and -0.7% below the high.

Moderna(MRNA) shares are trading with a volume of 43.36K, against a daily average of 16.82M.

In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.

In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.

MRNA News

Simply Wall St 5h
Moderna Shifts Vaccine Funding Approach And Expands mRNA Oncology Ambitions

Moderna (NasdaqGS:MRNA) plans to stop funding new Phase III vaccine trials in the U.S., citing a more hostile vaccine climate. The company aims to secure exter...

Moderna Shifts Vaccine Funding Approach And Expands mRNA Oncology Ambitions
TipRanks 2d
Moderna assumed with an Equal Weight at Barclays

Barclays analyst Eliana Merle assumed coverage of Moderna (MRNA) with an Equal Weight rating and $25 price target Barclays initiated coverage of 12 biotech stoc...

TipRanks 3d
Moderna and Merck Advance Phase 3 Cancer Vaccine Combo in Lung Cancer: What Investors Should Know

Moderna (MRNA) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Study Overview This Phase 3 study, officially titled “A Ph...

Analyst ratings

74%

of 27 ratings
Buy
11.1%
Hold
74.1%
Sell
14.8%

More MRNA News

TipRanks 5d
Moderna’s Cancer Bets Ignite Powerful Stock Rebound

Moderna ( (MRNA) ) has risen by 16.45%. Read on to learn why. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for smart...

TipRanks 6d
Moderna and Merck Advance Personalized mRNA Cancer Vaccine Into Phase 2 Bladder Cancer Trial

Moderna (MRNA) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for...

Seeking Alpha 7d
Moderna cutting R&D on vaccines amid U.S. pushback: CEO

Moderna (MRNA) CEO Stéphane Bancel said on Thursday that his company will not fund further late-stage development of vaccines as the U.S. government pushes back...

Moderna cutting R&D on vaccines amid U.S. pushback: CEO
TipRanks 7d
Moderna Stock Jumps 10% on Positive Results for Cancer Drug

Shares of drug maker Moderna (MRNA) are up 10% on Jan. 22 after the company reported positive trial results for its newest cancer drug. Claim 50% Off TipRanks...

Sherwood News 7d
Moderna extends rally on positive cancer vaccine results

Moderna extends rally on positive cancer vaccine results Moderna has more than doubled since it announced on Tuesday that its cancer vaccine reduced the risk o...

Moderna extends rally on positive cancer vaccine results
TipRanks 7d
Moderna curbs investment in vaccine trials due to U.S. backlash, Bloomberg says

Moderna’s (MRNA) chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of growing opposition to immunizations...

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.